Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$86.72 USD

86.72
4,365,080

-0.64 (-0.73%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $86.73 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Drug/Biotech Stocks' Q3 Earnings on Oct 27: MRK, GILD & More

by Zacks Equity Research

Let's analyze how the four pharma/drug/biotech companies are placed before the quarterly earnings release on Oct 27.

Why Gilead (GILD) Could Beat Earnings Estimates Again

by Zacks Equity Research

Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

What's in Store for Gilead (GILD) This Earnings Season?

by Zacks Equity Research

Investors focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports third-quarter 2022 results.

Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Gilead (GILD) Inks Deal for Gene Platform in Blood Cancers

by Zacks Equity Research

Gilead (GILD) signs a license agreement with Refuge Biotechnologies to use the latter's gene expression platform to develop treatments for blood cancers.

Analysts Estimate Gilead Sciences (GILD) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Gilead Sciences (GILD) closed the most recent trading day at $66.19, moving -1.02% from the previous trading session.

Gilead's (GILD) Yescarta Gets EC Nod for New Cancer Indication

by Zacks Equity Research

The European Commission approves Gilead's (GILD) CAR T-cell therapy, Yescarta, for treating adult patients with second-line diffuse large b-cell lymphoma and high-grade b-cell lymphoma.

Neena Mishra headshot

Why Cash Rich Companies, ETFs are Beating the Market

by Neena Mishra

We discuss Cash Cows & Trendpilot ETFs.

Gilead Sciences (GILD) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, Gilead Sciences (GILD) closed at $66.46, marking a +1.64% move from the previous day.

Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know

by Zacks Equity Research

Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Biotech Stock Roundup: DICE Up on Study Data, GILD, BIIB's Updates & More

by Zacks Equity Research

Regulatory and pipeline updates from DICE and RIGL are the key highlights from the biotech sector during the past week.

Gilead (GILD) Trodelvy Label Expansion sBLA Gets Priority Review

by Zacks Equity Research

Gilead's (GILD) efforts to expand Trodelvy's label progress, as the FDA accepts sBLA for the same and grants Priority Review.

Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Gilead Sciences (GILD) closed at $64.46 in the latest trading session, marking a +0.26% move from the prior day.

Gilead (GILD) Up 2.6% in 3 Months: Will the Momentum Continue?

by Zacks Equity Research

Gilead (GILD) is having a good run despite the volatility on a string of positive updates.

Gilead Sciences (GILD) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Gilead Sciences (GILD) closed at $62.32 in the latest trading session, marking a +1.02% move from the prior day.

Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for PJP

Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Gilead Sciences (GILD) closed the most recent trading day at $62.63, moving +0.47% from the previous trading session.

The Zacks Analyst Blog Highlights Union Pacific, AT&T, Blackstone, Gilead Sciences and Waste Management

by Zacks Equity Research

Union Pacific, AT&T, Blackstone, Gilead Sciences and Waste Management are included in this Analyst Blog.

Sheraz Mian headshot

Top Research Reports for Union Pacific, AT&T & Blackstone

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Union Pacific Corporation (UNP), AT&T Inc. (T) and Blackstone Inc. (BX).

Biotech Stock Roundup: GILD, BMY's Regulatory News, BLUE's Therapy Approval & More

by Zacks Equity Research

Regulatory and pipeline updates from BMY and GILD are the key highlights from the biotech sector during the past week.

Should Franklin U.S. Low Volatility High Dividend Index ETF (LVHD) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for LVHD

Gilead Sciences (GILD) Stock Moves -1.67%: What You Should Know

by Zacks Equity Research

Gilead Sciences (GILD) closed at $63.50 in the latest trading session, marking a -1.67% move from the prior day.

Merck (MRK) Resumes HIV Studies on Islatravir With Lower Dose

by Zacks Equity Research

Merck's (MRK) new phase III studies are set to evaluate a once-daily oral combination of doravirine and a lower dose of islatravir

Gilead (GILD) Drugs Get Positive CHMP Opinion for Label Expansion

by Zacks Equity Research

Gilead's (GILD) COVID-19 treatment Veklury and CAR T-cell therapy Yescarta get positive CHMP recommendation for additional indications.